Unaudited NAV for August 2023

14.09.23 08:00 Uhr

Arix Bioscience PLC (ARIX)
Unaudited NAV for August 2023

14-Sep-2023 / 07:00 GMT/BST

Arix Bioscience plc

LONDON, 14 September 2023: Arix Bioscience plc (Arix or the Company) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited estimated Net Asset Value (NAV) of the Company for the date ended 31 August 2023 as follows:

Date

NAV Breakdown

Total NAV

NAV per share

Listed Portfolio

Unlisted Portfolio

Cash

Other Interests

31 August 2023

(unaudited)

£66.9m

£66.2m

£100m

£2.8m

£235.9m

£1.82

[ENDS]

Enquiries

For more information on Arix, please contact:

Arix Bioscience plc

+44 (0)20 7290 1050

ir@arixbioscience.com

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil, Nick Johnson

+44 (0)20 7250 1446

arix@powerscourt-group.com

About Arix Bioscience plc

Arix Bioscience plc is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


ISIN:	GB00BD045071
Category Code:	MSCL
TIDM:	ARIX
LEI Code:	213800OVT3AHQCXNIX43
OAM Categories:	3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.:	271278
EQS News ID:	1725643